Literature DB >> 23224128

[Clarithromycin therapy of a B cell MALT lymphoma].

L Danilko1, K Haas, U Schönherr, G Tschurtschenthaler.   

Abstract

Presentation of a 34-year-old patient with a conjunctival tumor of the left upper circumference of the eyeball clinically presenting as a salmon-pink colored conjunctival tumor. The incisional biopsy and immunohistochemical work-up revealed an extranodal conjunctival mucosa-associated lymphoid tissue (MALT) lymphoma of the marginal zone B cell type. The therapy comprised a currently experimental therapy scheme with 500 mg clarithromycin 3 times per day for 21 days. This therapy achieved a significant tumor regression.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23224128     DOI: 10.1007/s00347-012-2724-7

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  5 in total

1.  Six-month oral clarithromycin regimen is safe and active in extranodal marginal zone B-cell lymphomas: final results of a single-centre phase II trial.

Authors:  Silvia Govi; Giuseppina P Dognini; Giada Licata; Roberto Crocchiolo; Antonio Giordano Resti; Maurilio Ponzoni; Andrés J M Ferreri
Journal:  Br J Haematol       Date:  2010-04-28       Impact factor: 6.998

2.  Lymphoid hyperplasia and malignant lymphoma occurring in the ocular adnexa (orbit, conjunctiva, and eyelids): a prospective multiparametric analysis of 108 cases during 1977 to 1987.

Authors:  D M Knowles; F A Jakobiec; L McNally; J S Burke
Journal:  Hum Pathol       Date:  1990-09       Impact factor: 3.466

3.  High relapse rate in patients with MALT lymphoma warrants lifelong follow-up.

Authors:  Markus Raderer; Berthold Streubel; Stefan Woehrer; Andreas Puespoek; Ulrich Jaeger; Michael Formanek; Andreas Chott
Journal:  Clin Cancer Res       Date:  2005-05-01       Impact factor: 12.531

4.  Assessment of disease dissemination in gastric compared with extragastric mucosa-associated lymphoid tissue lymphoma using extensive staging: a single-center experience.

Authors:  Markus Raderer; Stefan Wöhrer; Berthold Streubel; Marlene Troch; Karl Turetschek; Ulrich Jäger; Cathrin Skrabs; Alexander Gaiger; Johannes Drach; Andreas Puespoek; Michael Formanek; Martha Hoffmann; Wolfgang Hauff; Andreas Chott
Journal:  J Clin Oncol       Date:  2006-06-12       Impact factor: 44.544

5.  Lymphoproliferative lesions of the ocular adnexa. Analysis of 112 cases.

Authors:  S E Coupland; L Krause; H J Delecluse; I Anagnostopoulos; H D Foss; M Hummel; N Bornfeld; W R Lee; H Stein
Journal:  Ophthalmology       Date:  1998-08       Impact factor: 12.079

  5 in total
  1 in total

1.  [Clarithromycin for monotherapy of B-cell MALT lymphoma?].

Authors:  C Auw-Hädrich; J Finke; A Serr; H Mittelviefhaus; C Bogdan; T Reinhard
Journal:  Ophthalmologe       Date:  2013-11       Impact factor: 1.059

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.